AEON Biopharma Reports Full Year 2025 Financial Results and Highlights Positive Comparative Analytical Results for ABP-450 Biosimilar Program

AEON Biopharma reported positive initial comparative analytical results and a positive FDA BPD Type 2a meeting for its ABP-450 biosimilar program. The results confirmed identical amino-acid sequencing and highly similar functional characteristics to BOTOX. The company also strengthened its balance sheet through a $6 million PIPE financing and Daewoong note exchange, reducing outstanding debt by over 90%. John Bencich was appointed Chief Financial Officer, bringing significant capital markets and strategic leadership experience.